Unjoni Ewropea - Malti - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - imepitoin - antiepilletiċi oħra, anti-epilettiċi - klieb - għat-tnaqqis tal-frekwenza ta 'aċċessjonijiet ġeneralizzati minħabba epilessija idjopatika fi klieb għall-użu wara evalwazzjoni bir-reqqa ta' għażliet alternattivi ta 'trattament.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

glaxo group limited  - retigabine - epilessija - anti-epilettiċi, - trobalt huwa indikat bħala trattament adjunctive ta ' droga reżistenti b'sekwestru parzjali-iskoppjar bi jew mingħajr ġeneralizzazzjoni sekondarju fil-pazjenti li għandhom 18-il sena jew aktar bl-epilessija, fejn oħra tagħqid xieraq tad-droga, ġew ippruvati inadegwati jew ma jkunux ġew tollerat.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

bial - portela ca, s.a. - eslicarbazepine acetate - epilessija - anti-epilettiċi, - exalief huwa indikat bħala terapija aġġuntiva f'adulti b'aċċessjonijiet ta 'bidu parzjali b'ġeneralizzazzjoni sekondarja jew mingħajrha.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

angelini pharma s.p.a - cenobamate - epilessija - anti-epilettiċi, - adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic medicinal products.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - aġenti antineoplastiċi - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - aġenti antineoplastiċi - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

janssen-cilag international n.v. - talquetamab - majloma multipla - aġenti antineoplastiċi - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - aġenti antineoplastiċi - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

eisai gmbh - perampanel - epilettiji, parzjali - anti-epilettiċi, , anti-epilettiċi oħrajn - fycompa huwa indikat għat-trattament aġġuntiv ta 'attakki ta' bidu parzjali b'aċċessjonijiet sekondarji ġeneralizzati jew mingħar sekondarji f'pazjenti adulti u adolexxenti minn 12-il sena b'epilessija. fycompa huwa indikat għat-trattament aġġuntiv tal-seizures tonic-clonic ġeneralizzati fl-adulti u pazjenti adolexxenti minn 12 il-sena b'epilessija ġeneralizzata idjopatika.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - aġenti antineoplastiċi - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.